Ovid Therapeutics (NASDAQ:OVID – Get Free Report) and Mindset Pharma (OTCMKTS:MSSTF – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.
Institutional & Insider Ownership
56.6% of Ovid Therapeutics shares are owned by institutional investors. 12.6% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Ovid Therapeutics and Mindset Pharma’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ovid Therapeutics||$1.50 million||178.38||-$54.17 million||($0.70)||-5.41|
This is a breakdown of recent recommendations for Ovid Therapeutics and Mindset Pharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ovid Therapeutics currently has a consensus price target of $2.50, suggesting a potential downside of 34.04%. Mindset Pharma has a consensus price target of $5.00, suggesting a potential upside of 819.12%. Given Mindset Pharma’s higher possible upside, analysts clearly believe Mindset Pharma is more favorable than Ovid Therapeutics.
This table compares Ovid Therapeutics and Mindset Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Mindset Pharma beats Ovid Therapeutics on 5 of the 8 factors compared between the two stocks.
About Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
About Mindset Pharma
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.